Back to top
more

Sangamo Therapeutics (SGMO)

(Delayed Data from NSDQ)

$0.38 USD

0.38
4,780,386

0.00 (0.16%)

Updated Mar 6, 2026 04:00 PM ET

After-Market: $0.38 0.00 (0.66%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.86%
2Buy18.17%
3Hold10.12%
4Sell5.62%
5Strong Sell2.90%
S&P50011.43%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (90 out of 243)

Industry: Medical - Biomedical and Genetics

Brokerage Reports

Research for SGMO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Sangamo Therapeutics, Inc. [SGMO]

Reports for Purchase

Showing records 1 - 20 ( 348 total )

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

01/13/2026

Industry Report

Pages: 7

Day 1 Meetings in SFO: Durability, Regulatory Efficiency, and Execution Drive Investable Themes

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

01/13/2026

Industry Report

Pages: 7

Day 1 Meetings in SFO: Durability, Regulatory Efficiency, and Execution Drive Investable Themes

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

11/21/2025

Daily Note

Pages: 3

Fabry BLA Request for Rolling Submission Accepted by FDA; Accelerated Approval Path Confirmed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

11/10/2025

Company Report

Pages: 9

Minutes From October Meeting With FDA Reinforce Accelerated Path in Fabry With BLA on Track for 1Q26; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

09/04/2025

Daily Note

Pages: 5

Fabry STAAR Shines at ICIEM With BLA on Track for 1Q26; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

09/04/2025

Daily Note

Pages: 5

Fabry STAAR Shines at ICIEM With BLA on Track for 1Q26; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

08/12/2025

Company Report

Pages: 8

Fabry BLA in 1Q26, Neurology Readouts, and BD Momentum

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

06/30/2025

Industry Report

Pages: 105

Neuro Perspectives 2025: What We Learned-and Where CNS Is Headed

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 150.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

06/24/2025

Daily Note

Pages: 3

Top-Line Data From Registrational Trial in Fabry Disease Support BLA in 2026; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

05/28/2025

Company Report

Pages: 8

BioConnect Takeaways: Prion Disease CTA Filing and Fabry BLA on Track for 1Q26

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

05/14/2025

Company Report

Pages: 9

Prion Disease Program Shines at ASGCT; CTA Filing on Track for 1Q26; Genomic Medicines Pipeline Advancing; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

05/05/2025

Daily Note

Pages: 5

ASGCT 2025 Preview: Precision, Safety, and Neurology Drive Catalyst-Rich Space

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

04/22/2025

Industry Report

Pages: 25

Policy Crosscurrents in 2025: Regulatory Acceleration, Pricing Pressure, and the Trump 2.0 Paradox

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 75.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

04/07/2025

Company Report

Pages: 10

BLA, Biobucks, and Beyond: Neurology Genomic Medicines Pipeline Positioned for a Breakout Year

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

01/27/2025

Company Report

Pages: 8

Management Breakfast Foreshadows Potential Positive Developments on the Pipeline; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

12/31/2024

Daily Note

Pages: 3

Regains Rights to Hemophilia A Program

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

12/19/2024

Daily Note

Pages: 3

Brain-Targeted AAV Capsid Fosters Another Pharma Deal in the Neurology Space

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

12/10/2024

Daily Note

Pages: 6

One-Time Gene Therapy in Hemophilia A Shines at ASH; Expect Potential Approval in 2025; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

11/14/2024

Daily Note

Pages: 8

Clear Clinical Development Plan for Gene Therapy Program in Fabry Disease

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

11/05/2024

Company Report

Pages: 9

High Confidence on Path to Approval in Lead Fabry Gene Therapy Program; Upping Price Target to $10; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party